Subtopic Deep Dive
Sigma-1 Receptor in Neuropsychiatric Disorders
Research Guide
What is Sigma-1 Receptor in Neuropsychiatric Disorders?
Sigma-1 receptor (S1R) is an endoplasmic reticulum chaperone modulating neuroplasticity, monoamine systems, and neuroinflammation in depression, anxiety, and addiction disorders.
S1R ligands like fluvoxamine influence antidepressant responses and cognitive deficits in models of schizophrenia (Hashimoto et al., 2006, 137 citations). Research links S1R polymorphisms to neuropsychiatric treatment outcomes through chaperone signaling (Hayashi et al., 2011, 198 citations). Over 1,500 papers explore S1R pharmacology since 2004.
Why It Matters
S1R agonists advance treatments for depression and addiction by enhancing neurorestoration, as shown in parkinsonism models adaptable to mood disorders (Francardo et al., 2014, 195 citations). Fluvoxamine's S1R activation reduces cognitive deficits in phencyclidine models, supporting repurposing for schizophrenia (Hashimoto et al., 2006, 137 citations). Psychedelics like DMT target S1R to suppress inflammation in immune cells, offering novel anti-anxiety therapies (Szabó et al., 2014, 174 citations).
Key Research Challenges
Ligand Selectivity Issues
Distinguishing sigma-1 from sigma-2 effects remains difficult due to overlapping binding profiles (Cobos et al., 2008, 367 citations). Off-target actions complicate clinical translation in depression trials. Selective agonists are needed for neuropsychiatric specificity.
Downstream Signaling Gaps
Intracellular cascades from S1R activation in neuroplasticity are partially mapped, limiting mechanism-based therapies (Hayashi et al., 2011, 198 citations). Polymorphism impacts on monoamine modulation require genetic studies. Chaperone functions in anxiety need clarification.
Clinical Translation Barriers
Preclinical neurorestorative effects in addiction models lack large-scale human validation (Francardo et al., 2014, 195 citations). Dose-response for fluvoxamine in cognitive disorders is underexplored (Hashimoto et al., 2006, 137 citations). Biomarker development for patient stratification is absent.
Essential Papers
Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands
Enrique J. Cobos, José Manuel Entrena, Francisco R. Nieto et al. · 2008 · Current Neuropharmacology · 367 citations
Sigma (sigma) receptors, initially described as a subtype of opioid receptors, are now considered unique receptors. Pharmacological studies have distinguished two types of sigma receptors, termed s...
??-1 Receptor Ligands
Teruo Hayashi, Tsung‐Ping Su · 2004 · CNS Drugs · 292 citations
Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders
Teruo Hayashi, Shang‐Yi Tsai, Tomohisa Mori et al. · 2011 · Expert Opinion on Therapeutic Targets · 198 citations
The advances in sigma receptor research in the last decade have begun to elucidate the intracellular signal cascades upstream and downstream of sigma-1 receptors. The novel ligand-operated properti...
Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases
Daniel A. Ryskamp, Svetlana A. Korban, Vladimir Zhemkov et al. · 2019 · Frontiers in Neuroscience · 195 citations
Sigma-1 receptor (S1R) is a multi-functional, ligand-operated protein situated in endoplasmic reticulum (ER) membranes and changes in its function and/or expression have been associated with variou...
Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism
Veronica Francardo, Francesco Bez, Tadeusz Wieloch et al. · 2014 · Brain · 195 citations
The sigma-1 receptor, an endoplasmic reticulum-associated molecular chaperone, is attracting great interest as a potential target for neuroprotective treatments. We provide the first evidence that ...
Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19
Vikas P. Sukhatme, Angela M. Reiersen, Sharat J. Vayttaden et al. · 2021 · Frontiers in Pharmacology · 189 citations
Fluvoxamine is a well-tolerated, widely available, inexpensive selective serotonin reuptake inhibitor that has been shown in a small, double-blind, placebo-controlled, randomized study to prevent c...
Psychedelic N,N-Dimethyltryptamine and 5-Methoxy-N,N-Dimethyltryptamine Modulate Innate and Adaptive Inflammatory Responses through the Sigma-1 Receptor of Human Monocyte-Derived Dendritic Cells
Attila Szabó, A. Kovács, Ede Frecska et al. · 2014 · PLoS ONE · 174 citations
The orphan receptor sigma-1 (sigmar-1) is a transmembrane chaperone protein expressed in both the central nervous system and in immune cells. It has been shown to regulate neuronal differentiation ...
Reading Guide
Foundational Papers
Start with Cobos et al. (2008, 367 citations) for sigma-1 pharmacology basics, then Hayashi et al. (2004, 292 citations) for ligand mechanisms, and Hayashi et al. (2011, 198 citations) for neuropsychiatric signaling cascades.
Recent Advances
Study Ryskamp et al. (2019, 195 citations) for neuronal protective roles and Sukhatme et al. (2021, 189 citations) for fluvoxamine's S1R-mediated effects.
Core Methods
Core techniques include ligand binding assays, mouse behavioral models (phencyclidine-induced deficits), and ER chaperone signaling analysis via agonists like PRE-084 (Francardo et al., 2014).
How PapersFlow Helps You Research Sigma-1 Receptor in Neuropsychiatric Disorders
Discover & Search
Research Agent uses searchPapers('sigma-1 receptor depression fluvoxamine') to find 500+ papers, then citationGraph on Cobos et al. (2008) reveals 367-cited networks linking to Hayashi et al. (2011). findSimilarPapers expands to addiction studies; exaSearch uncovers polymorphism data.
Analyze & Verify
Analysis Agent applies readPaperContent on Hashimoto et al. (2006) to extract fluvoxamine dose-responses, verifies claims with CoVe against 10 similar papers, and runs PythonAnalysis (pandas correlation on citation metadata) with GRADE scoring for evidence strength in cognitive models.
Synthesize & Write
Synthesis Agent detects gaps in S1R polymorphism studies via contradiction flagging across 50 papers; Writing Agent uses latexEditText for review drafting, latexSyncCitations for 20 references, and latexCompile for publication-ready PDF with exportMermaid diagrams of signaling cascades.
Use Cases
"Analyze fluvoxamine sigma-1 effects on mouse cognition data from Hashimoto 2006."
Analysis Agent → readPaperContent (Hashimoto et al., 2006) → runPythonAnalysis (plot deficit improvements with matplotlib) → GRADE-verified statistical summary of subchronic dosing outcomes.
"Draft LaTeX review on sigma-1 in depression with citations."
Synthesis Agent → gap detection (20 papers) → Writing Agent → latexEditText (structure sections) → latexSyncCitations (Cobos 2008, Hayashi 2011) → latexCompile (export PDF with figures).
"Find GitHub code for sigma-1 receptor binding simulations."
Research Agent → paperExtractUrls (Francardo et al., 2014) → paperFindGithubRepo → githubRepoInspect (analyze parkinsonism model scripts) → runPythonAnalysis (replicate neurorestorative simulations).
Automated Workflows
Deep Research workflow scans 50+ S1R papers for systematic review on depression, chaining searchPapers → citationGraph → DeepScan (7-step verification with CoVe checkpoints). Theorizer generates hypotheses on fluvoxamine polymorphisms from Hayashi et al. (2011) literature synthesis. DeepScan analyzes signaling gaps with runPythonAnalysis on chaperone networks.
Frequently Asked Questions
What defines sigma-1 receptor in neuropsychiatry?
Sigma-1 receptor is a ligand-operated ER chaperone regulating neuroplasticity and monoamine modulation in depression, anxiety, and addiction (Hayashi et al., 2011).
What are key methods for S1R research?
Pharmacological assays use selective ligands like fluvoxamine in mouse phencyclidine models for cognition (Hashimoto et al., 2006); chaperone signaling is studied via intracellular cascades (Hayashi et al., 2004).
What are top papers on S1R ligands?
Cobos et al. (2008, 367 citations) details pharmacology; Hayashi et al. (2011, 198 citations) covers therapeutic targeting in disorders.
What open problems exist?
Selective ligand development, human polymorphism validation, and biomarker identification for clinical translation remain unsolved (Francardo et al., 2014).
Research Pharmacological Receptor Mechanisms and Effects with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Sigma-1 Receptor in Neuropsychiatric Disorders with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers